Browsing Tag
SunRISe-1 Study
1 post
Johnson & Johnson’s TAR-200 delivers over 80% disease-free survival, offering new hope in BCG-unresponsive high-risk papillary NMIBC
Discover how Johnson & Johnson’s TAR-200 is redefining bladder cancer treatment with over 80% disease-free survival and 94% bladder preservation today!